While the evidence is very preliminary, it is thought that SGLT2 inhibitors may suppress glomerular hyperfiltration, hypoglycemia-related tubular growth, kidney hypertrophy, and other harbingers of diabetic nephropathy.
Are you a US-based MD who sees patients with diabetes and likes to write? Why not blog for EndocrinologyNetwork.com? Be heard on topics that keep you up at night. Contact us here and we can send you the details.